Amicus To See If Its Fabry Drug Galafold Can Benefit From Mis-Diagnosed MS
Executive Summary
Rare disease specialist Amicus Therapeutics' lead product Galafold has recently launched with early success and the company's president tells Scrip further momentum could come from better Fabry disease diagnosis.
You may also be interested in...
Amicus Piggybacks Off Galafold Commercial Infrastructure For Pombiliti + Opfolda Launch
The company anticipates potential sales in excess of $1bn for the late-onset Pompe disease drug by the end of the decade.
Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT
FDA approved Galafold under accelerated approval, paving the way for the launch of the first oral therapy to treat a subset of patients with the rare condition Fabry disease. Amicus priced Galafold at $315,000 per year.